Erik Vandendries

4.9k total citations · 2 hit papers
88 papers, 3.5k citations indexed

About

Erik Vandendries is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Hematology. According to data from OpenAlex, Erik Vandendries has authored 88 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Public Health, Environmental and Occupational Health, 47 papers in Oncology and 45 papers in Hematology. Recurrent topics in Erik Vandendries's work include Acute Lymphoblastic Leukemia research (49 papers), CAR-T cell therapy research (39 papers) and Lymphoma Diagnosis and Treatment (28 papers). Erik Vandendries is often cited by papers focused on Acute Lymphoblastic Leukemia research (49 papers), CAR-T cell therapy research (39 papers) and Lymphoma Diagnosis and Treatment (28 papers). Erik Vandendries collaborates with scholars based in United States, Germany and United Kingdom. Erik Vandendries's co-authors include Anjali S. Advani, Bruce Furie, Barbara C. Furie, Daniel J. DeAngelo, Hagop M. Kantarjian, Wendy Stock, Matthias Stelljes, Michaela Liedtke, Nicola Gökbuget and Barbara Sleight and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

Erik Vandendries

85 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

2016 869 citations Hagop M. Kantarjian, Daniel J. DeAngelo et al. profile →
Accumulation of Tissue Factor into Developing Thrombi In Vivo Is Dependent upon Microparticle P-Selectin Glycoprotein Ligand 1 and Platelet P-Selectin

2003 581 citations Erik Vandendries, Barbara C. Furie et al. profile →

Peers

Countries citing papers authored by Erik Vandendries

Since Specialization

Citations

This map shows the geographic impact of Erik Vandendries's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Vandendries with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Vandendries more than expected).

Fields of papers citing papers by Erik Vandendries

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Vandendries. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Vandendries. The network helps show where Erik Vandendries may publish in the future.

Co-authorship network of co-authors of Erik Vandendries

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Vandendries. A scholar is included among the top collaborators of Erik Vandendries based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Vandendries. Erik Vandendries is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study 2025 ·Haematologica ·Muhıt Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, (unknown), Ying Chen, Alejandra Nieto, Fatih Demırkan, Pau Montesinos, Fevzi Altuntaş	1
2	Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial 2025 ·Blood ·Attaya Suvannasankha, Jonathan L. Kaufman, Ashraf Badros, Michel Pavic, (unknown), (unknown), Parth Shah, Patrick J. Mueller, Jorge Acosta‐Reyes, Margaret Hoyle, Erik Vandendries, Jie‐Fei Cheng, Alexander M. Lesokhin	0
3	A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Mohamed Elmeliegy, Diane Wang, Erik Vandendries, (unknown), (unknown), Jason H. Williams	1
4	MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab (ELRA) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) 2024 ·Blood ·Matthew J. Pianko, Charlotte Pawlyn, Shang‐Yi Huang, Tadao Ishida, Douglas W. Sborov, Shinsuke Iida, Aravind Ramakrishnan, (unknown), Rakesh Popat, Steven R. Schuster, Junya Kuroda, Chia-Jen Liu, Anne Philippe, Umberto Conte, Fangxin Hong, Erik Vandendries, Rafaël Fonseca	0
5	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 2021 ·Clinical Cancer Research ·Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan O’Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin T. Nguyen, Barbara Sleight, Erik Vandendries, (unknown), Alexander Laird, Anjali S. Advani	29
6	Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia 2021 ·Bone Marrow Transplantation ·Cécile Pautas, Emmanuel Raffoux, Juliette Lambert, Ollivier Legrand, Sylvain Chantepie, Lauris Gastaud, Jean‐Pierre Marolleau, Xavier Thomas, Pascal Turlure, Rebecca Benner, Erik Vandendries, Karı̈n Gogat, Hervé Dombret, Sylvie Castaigné	13
7	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial 2019 ·Leukemia Research ·(unknown), Nicola Gökbuget, Anjali S. Advani, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Giovanni Martinelli, Susan O’Brien, Tao Wang, Alexander Laird, Erik Vandendries, (unknown), Kevin T. Nguyen, Naveen Dakappagari, Daniel J. DeAngelo, Hagop Kantarjian	37
8	Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia 2019 ·International Journal of Hematology ·Naohito Fujishima, Toshiki Uchida, Yasushi Onishi, Chul Won Jung, Yeow Tee Goh, Kiyoshi Ando, (unknown), Chiho Ono, (unknown), M. Luisa Paccagnella, Barbara Sleight, Erik Vandendries, Yosuke Fujii, Masayuki Hino	8
9	Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) 2018 ·Biology of Blood and Marrow Transplantation ·Partow Kebriaei, Matthias Stelljes, Daniel J. DeAngelo, Nicola Gökbuget, Hagop M. Kantarjian, Anjali S. Advani, Akil Merchant, Wendy Stock, Tao Wang, Hui Zhang, Fausto R. Loberiza, Erik Vandendries, David I. Marks	1
10	Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study 2017 ·Blood ·Hagop M. Kantarjian, Daniel J. DeAngelo, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Goekbuget, Susan O’Brien, Elias Jabbour, Tao Wang, Jane Liang White, Barbara Sleight, Erik Vandendries, Anjali S. Advani	5
11	Indirect Treatment Comparison (ITC) of Inotuzumab Ozogamicin (InO) and Blinatumomab (Blina) for Relapsed or Refractory (RR) Acute Lymphoblastic Leukemia (ALL) 2017 ·Blood ·Matthias Stelljes, Yun Su, Kyle Fahrbach, Erik Vandendries, Véronique Pagé, (unknown), Yunyang Wang, Joseph C. Cappelleri, Irina Proskorovsky	1
12	Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status 2017 ·Blood ·Anjali S. Advani, Elias Jabbour, Matthias Stelljes, Wendy Stock, Michaela Liedtke, Nicola Goekbuget, Susan O’Brien, Jane Liang White, Tao Wang, Alexander Laird, Erik Vandendries, Hagop M. Kantarjian	2
13	Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma 2016 ·Clinical Cancer Research ·Michinori Ogura, Kensei Tobinai, Kiyohiko Hatake, Andrew Davies, Michael Crump, Revathi Ananthakrishnan, (unknown), M. Luisa Paccagnella, Joseph Boni, Erik Vandendries, David MacDonald	28
14	A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy 2016 ·British Journal of Haematology ·André Goy, Andres Forero, Nina D. Wagner‐Johnston, W. Christopher Ehmann, Michaela L. Tsai, Kiyohiko Hatake, Revathi Ananthakrishnan, Angela Volkert, Erik Vandendries, Michinori Ogura	40
15	Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab 2013 ·Journal of Clinical Oncology ·Luis Fayad, Fritz Offner, Mitchell R. Smith, Gregor Verhoef, Peter Johnson, Jonathan L. Kaufman, A. Z. S. Rohatiner, Anjali S. Advani, James M. Foran, Georg Heß, Bertrand Coiffier, Myron S. Czuczman, Eva Giné, Simon Durrant, Michelle Kneissl, Kenneth T. Luu, Steven Y. Hua, Joseph Boni, Erik Vandendries, Nam H. Dang	119
16	Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma 2012 ·Cancer Science ·Michinori Ogura, Kiyohiko Hatake, Kiyoshi Ando, Kensei Tobinai, (unknown), Chiho Ono, (unknown), Erik Vandendries	55
17	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study 2010 ·Journal of Clinical Oncology ·Anjali S. Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James M. Foran, Eva Giné, Christian Gisselbrecht, Nicolas Ketterer, Sunita D. Nasta, A. Z. S. Rohatiner, Ingo G.H. Schmidt‐Wolf, Martin Schüler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad	255
18	Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma 2010 ·Ghent University Academic Bibliography (Ghent University) ·Gregor Verhoef, (unknown), Mitchell R. Smith, (unknown), Peter Johnson, A. Z. S. Rohatiner, (unknown), Eva Giné, B Coiffier, M. S. Czuczman, James M. Foran, Simon Durrant, Steven Y. Hua, Erik Vandendries, Joseph Boni, Luis Fayad	2
19	Role of P-selectin and PSGL-1 in coagulation and thrombosis 2004 ·Thrombosis and Haemostasis ·Erik Vandendries, Barbara C. Furie, Bruce Furie	173
20	orthodenticleIs Required for Photoreceptor Cell Development in theDrosophilaEye 1996 ·Developmental Biology ·Erik Vandendries, Denise Johnson, Rosemary Reinke	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact